Jpmorgan Chase & CO Arcus Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 42,568 shares of RCUS stock, worth $662,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,568

Previous 40,226 5.82%

Holding current value

$662,358

Previous $759,000 14.62%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$14.59 - $18.48 $34,169 - $43,280	2,342 Added 5.82%	42,568 $648,000
Q1 2024 May 10, 2024	SELL	$14.83 - $20.18 $588,187 - $800,379	-39,662 Reduced 49.65%	40,226 $759,000
Q4 2023 Feb 12, 2024	BUY	$13.43 - $19.63 $21,071 - $30,799	1,569 Added 2.0%	79,888 $1.53 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $26,095 - $34,862	-1,481 Reduced 1.86%	78,319 $1.41 Million
Q2 2023 Aug 11, 2023	SELL	$16.97 - $22.03 $7.81 Million - $10.1 Million	-460,195 Reduced 85.22%	79,800 $1.62 Million
Q1 2023 May 18, 2023	BUY	$15.96 - $23.15 $1.04 Million - $1.5 Million	64,878 Added 13.66%	539,995 $9.85 Million
Q1 2023 May 11, 2023	SELL	$15.96 - $23.15 $635,112 - $921,231	-39,794 Reduced 7.73%	475,117 $8.67 Million
Q4 2022 Feb 13, 2023	BUY	$19.7 - $35.71 $220,206 - $399,166	11,178 Added 2.22%	514,911 $10.6 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $312,652 - $404,712	-13,459 Reduced 2.6%	503,733 $13.2 Million
Q2 2022 Aug 11, 2022	BUY	$17.23 - $37.73 $1.4 Million - $3.07 Million	81,399 Added 18.68%	517,192 $13.1 Million
Q1 2022 May 11, 2022	BUY	$28.92 - $41.83 $4.84 Million - $7 Million	167,381 Added 62.36%	435,793 $13.8 Million
Q4 2021 Feb 10, 2022	SELL	$31.38 - $48.47 $29,716 - $45,901	-947 Reduced 0.35%	268,412 $10.9 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $7.25 Million - $10.1 Million	269,359 New	269,359 $9.39 Million

Others Institutions Holding RCUS

# of Institutions

202

Shares Held

48.8M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Arcus Biosciences, Inc. Transaction History